ହାଇଡ୍ରକ୍ସିଇଥାଇଲ ଷ୍ଟାର୍ଚ

ହାଇଡ୍ରକ୍ସିଇଥାଇଲ ଷ୍ଟାର୍ଚ
Clinical data
Trade names	Hespan, Voluven, Volulyte, Tetrahes, Hestar, Others
Synonyms	Tetrastarch, hetastarch
AHFS/Drugs.com	HES 130/0.4: monograph; Hetastarch: monograph
Routes of; administration	Intravenous
Pharmacokinetic data
Elimination half-life	1.4 hrs
Excretion	Kidney
Identifiers
ECHA InfoCard	100.120.749
Chemical and physical data
Molar mass	130–200 kg/mol (typical)
3D model (JSmol)	Interactive image;
	SMILES O(CCO)[C@H]1O[C@@H]([C@@H](OCCO)[C@H](OCCO)[C@H]1OCCO)COCCO.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O;
	InChI InChI=1S/C16H32O11.C6H12O6/c17-1-6-22-11-12-13(23-7-2-18)14(24-8-3-19)15(25-9-4-20)16(27-12)26-10-5-21;7-1-2-3(8)4(9)5(10)6(11)12-2/h12-21H,1-11H2;2-11H,1H2/t12-,13-,14+,15-,16+;2-,3-,4+,5-,6+/m11/s1 ; Key:DNZMDASEFMLYBU-RNBXVSKKSA-N ;
(verify)

ହାଇଡ୍ରକ୍ସିଇଥାଇଲ ଷ୍ଟାର୍ଚ ( HES ), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଭଲ୍ୟୁଭେନ୍ ଏକ ବେପାର ନାମ, ଯାହା ଜୀବକୋଷ ବ‌ହିର୍ଭୁତ ତରଳ ପଦାର୍ଥର ପରିମାଣ କମୁଥିଲେ (ହାଇପୋଭୋଲେମିଆ)ର ତାହାର ପରିମାଣ ବୃଦ୍ଧି କରିବାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ^[୧] ସାଧାରଣତଃ କ୍ରିସ୍ଟାଲଏଡ (crystalloid) ବା କଲିଳ ଦ୍ରବଣ ଦେବାକୁ ଅଧିକ ପସନ୍ଦ କରାଯାଏ | ^[୧] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଗଲୁ ହୋଇପାରେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲାକ୍‌‌ସିସ, ରକ୍ତସ୍ରାବ, ହୃଦ୍‌ପାତ ଏବଂ ଶକ୍ ହୋଇପାରେ ।^[୧] ^[୨] ଗୁରୁତର ଅସୁସ୍ଥ ବ୍ୟକ୍ତିଙ୍କ ମୃତ୍ୟୁ ସମ୍ଭାବନା ଏବଂ ବୃକ୍‌କ ସମସ୍ୟା ହୋଇପାରେ ।^[୩] ଏହା ଏକ ଉତ୍ପାଦିତ କୋଲଏଡ ଦ୍ରବଣ ।^[୧]

୧୯୬୦ ଦଶକରେ ହାଇଡ୍ରକ୍ସିଇଥାଇଲ ଷ୍ଟାର୍ଚ ଡାକ୍ତରୀ ବ୍ୟବହାରରେ ଆସିଥିଲା ।^[୪] ୟୁରୋପ ୨୦୧୩ରେ ଏହାର ବ୍ୟବହାର ଉପରେ ପ୍ରତିବନ୍ଧକ ଲଗାଇଲା ଏବଂ ସଂପୃକ୍ତ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଯୋଗୁଁ ୨୦୧୮ରେ ସେମାନଙ୍କୁ ବଜାରରୁ ବାହାର କରିଦେଲା | ^[୫] ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ୫୦୦ ମିଲି ବ୍ୟାଗ ଥିବା ଏହାର ମୂଲ୍ୟ ୮୦ ଡଲାର ଥିଲା ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Hydroxyethyl Starch 130/0.4 Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 March 2016. Retrieved 10 December 2021.
↑ "Hetastarch Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 May 2016. Retrieved 10 December 2021.
↑ Zarychanski, R; Abou-Setta, AM; Turgeon, AF; Houston, BL; McIntyre, L; Marshall, JC; Fergusson, DA (Feb 20, 2013). "Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis". JAMA: The Journal of the American Medical Association. 309 (7): 678–88. doi:10.1001/jama.2013.430. PMID 23423413.
↑ Bilotta, F; Giordano, G; Caroletti, F; Pugliese, F (June 2018). "Hydroxyethyl starch: the Paradigm of Eminence-Based Versus Evidence-Based Medicine-1". Turkish journal of anaesthesiology and reanimation. 46 (3): 165–167. doi:10.5152/TJAR.2018.030618. PMID 30140509.
↑ "PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market". Archived from the original on 10 July 2021. Retrieved 10 December 2021.
↑ "Hydroxyethyl-starch solutions for infusion to be suspended – CMDh endorses PRAC recommendation". Archived from the original on 14 November 2021. Retrieved 10 December 2021.
↑ "Voluven Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 December 2021.

[AHFS2021HES-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Hydroxyethyl Starch 130/0.4 Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 March 2016. Retrieved 10 December 2021.

[AHFS2021HETA-2] "Hetastarch Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 May 2016. Retrieved 10 December 2021.

[Zar2013-3] Zarychanski, R; Abou-Setta, AM; Turgeon, AF; Houston, BL; McIntyre, L; Marshall, JC; Fergusson, DA (Feb 20, 2013). "Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis". JAMA: The Journal of the American Medical Association. 309 (7): 678–88. doi:10.1001/jama.2013.430. PMID 23423413.

[4] Bilotta, F; Giordano, G; Caroletti, F; Pugliese, F (June 2018). "Hydroxyethyl starch: the Paradigm of Eminence-Based Versus Evidence-Based Medicine-1". Turkish journal of anaesthesiology and reanimation. 46 (3): 165–167. doi:10.5152/TJAR.2018.030618. PMID 30140509.

[5] "PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market". Archived from the original on 10 July 2021. Retrieved 10 December 2021.

[6] "Hydroxyethyl-starch solutions for infusion to be suspended – CMDh endorses PRAC recommendation". Archived from the original on 14 November 2021. Retrieved 10 December 2021.

[7] "Voluven Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 December 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]